Global Congress on Prostate Cancer - PROSCA 2019

prosca.org

 

Global Congress on Prostate Cancer - PROSCA 2019
K

Navigating the Evolving Therapeutic Landscape in M1 Hormone-Sensitive Prostate Cancer: Current ADT Combo Options, Apalutamide/Enzalutamide as Alternative to Abiraterone, Triplet Therapy

By Global Congress on Prostate Cancer - PROSCA 2019 FEATURING Karim Fizazi
By Global Congress on Prostate Cancer - PROSCA 2019 FEATURING Karim Fizazi
20 views
January 10, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Metastatic Hormone-Sensitive Prostate Cancer
14:51
Global Congress on Prostate Cancer - PROSCA 2019

Local Therapy of the Primary in Metastatic Disease: RT Should Be Add…

Feat. T. Zilli
25:45
Global Congress on Prostate Cancer - PROSCA 2019

Navigating the Evolving Therapeutic Landscape in M1 Hormone-Sensitiv…

Feat. K. Fizazi
10:27
Global Congress on Prostate Cancer - PROSCA 2019

Case-Based Discussion: 61 y/o Man With De Novo Metastatic Hormone-Se…

Feat. M. Roach III, B. Tombal
21:21
Global Congress on Prostate Cancer - PROSCA 2019

Case-Based Discussion: 66 y/o Man With De Novo Metastatic Hormone-Se…

Feat. M. Roach III, B. Tombal